154 related articles for article (PubMed ID: 19955932)
1. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.
Risum S; Høgdall E; Engelholm SA; Fung E; Lomas L; Yip C; Petri AL; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2009 Dec; 19(9):1535-8. PubMed ID: 19955932
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
3. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2008 Feb; 108(2):265-70. PubMed ID: 18055006
[TBL] [Abstract][Full Text] [Related]
4. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
5. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
Obeidat B; Latimer J; Crawford R
Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
[TBL] [Abstract][Full Text] [Related]
6. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
[TBL] [Abstract][Full Text] [Related]
7. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.
Vorgias G; Iavazzo C; Savvopoulos P; Myriokefalitaki E; Katsoulis M; Kalinoglou N; Akrivos T
Gynecol Oncol; 2009 Jan; 112(1):11-5. PubMed ID: 19119502
[TBL] [Abstract][Full Text] [Related]
8. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
[TBL] [Abstract][Full Text] [Related]
9. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
[TBL] [Abstract][Full Text] [Related]
10. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
11. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
[TBL] [Abstract][Full Text] [Related]
12. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?
Saygili U; Guclu S; Uslu T; Erten O; Demir N; Onvural A
Gynecol Oncol; 2002 Jul; 86(1):57-61. PubMed ID: 12079301
[TBL] [Abstract][Full Text] [Related]
13. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
14. Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.
Ducoulombier S; Golfier F; Colomban O; Benayoun D; Bolze PA; Tod M; You B
Anticancer Res; 2017 Dec; 37(12):6879-6886. PubMed ID: 29187468
[TBL] [Abstract][Full Text] [Related]
15. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
[TBL] [Abstract][Full Text] [Related]
16. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
17. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
18. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
[TBL] [Abstract][Full Text] [Related]
19. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.
Bristow RE; Duska LR; Lambrou NC; Fishman EK; O'Neill MJ; Trimble EL; Montz FJ
Cancer; 2000 Oct; 89(7):1532-40. PubMed ID: 11013368
[TBL] [Abstract][Full Text] [Related]
20. Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022).
Jung DC; Kang S; Kim SC; Kim JW; Nam JH; Ryu SY; Seong SJ; Kim BG
Gynecol Oncol; 2013 Nov; 131(2):336-40. PubMed ID: 23954903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
